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Abstract
Intrauterine infection is considered as one of the major maternal insults during pregnancy.
Intrauterine infection during pregnancy could lead to brain damage of the developmental fetus and
offspring. Effects on the fetal, newborn, and adult central nervous system (CNS) may include signs
of neurological problems, developmental abnormalities and delays, and intellectual deficits.
However, the mechanisms or pathophysiology that leads to permanent brain damage during
development are complex and not fully understood. This damage may affect morphogenic and
behavioral phenotypes of the developed offspring, and that mice brain damage could be mediated
through a final common pathway, which includes over-stimulation of excitatory amino acid
receptor, over-production of vascularization/angiogenesis, pro-inflammatory cytokines,
neurotrophic factors and apoptotic-inducing factors.
Maternal insults during pregnancy
Several maternal insults during pregnancy are known as
major cause of fetal brain damage, including infection [1-
3]. Maternal insult was associated with morbidity and
mortality to infants, increased risk of intraventricular
hemorrhage, neonatal white matter damage, and subse-
quent cerebral palsy. The susceptibility of the immature
CNS to maternal insult is largely dependent on the tem-
poral and regional status of critical developmental proc-
esses, as well as on the regulation of cerebral blood flow
and metabolism. It was suggested that brain damage of
offspring, which belong to mothers who have suffered of
intrauterine infection/inflammation during pregnancy, is
mediated by neurotoxicity (2–4). The mechanisms or
pathophysiology of fetal neurotoxicity, induced by insult
exposure are complex and not fully understood. It is pos-
sible that intrauterine infection/inflammation is medi-
ated by factors that affect a final common pathway
leading to neuronal injury, such as initiation of apoptosis,
cellular dysfunction and death [1,2].
Systemic maternal infection and offspring brain 
damage
Clinical chorioamnionitis is considered as an infection of
the uterus and its contents during pregnancy. The inci-
dence varies between 10%–20%. According to histologi-
cal examination it is affected 20% of term as compared to
60% of the preterm deliveries. It was shown that clinical
and histopathological evidence of placental infection
were associated with an elevated risk of unexplained cere-
bral palsy (CP) [odds ratio (OR) 9.3, 95% confidence
interval (CI) 2.7, 31 for clinical chorioamnionitis (CA);
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OR 8.9, 95% CI 1.9, 40 for histology CA]). In addition,
the association between chorioamnionitis and cerebral
palsy was demonstrated using meta-analysis. Also, an
association between CA and both CP [relative risk (RR)
1.9; 95% CI 1.5, 2.5] and cystic periventricular leukoma-
lacia (cPVL) (RR 2.6; 95% CI 1.7, 3.9) was reported (for
excellent review see [5]). It was estimated that up to 12%
of spastic CP could be due to intrauterine infection and
inflammation [6].
There are specific periods in brain growth during which
the developing neurons are particularly susceptible to
growth restriction and could be affected by various envi-
ronmental agents including intrauterine infection during
pregnancy. It is suggested that the periods which could be
considered as "critical" in brain development is when cells
undergo mitosis (the main cells to be discussed are neu-
rons and glia) and also the correct and orderly sequence
of cellular migration and the formation of an appropriate
histological micro-architecture [7]. Although prolifera-
tion and differentiation of astrocytes in rats occurs mainly
during postnatal brain development [8], the presence of
radial glia (precursors of astrocytes) were also demon-
strated in rat fetal brain at embryonic day 15; from this
day the expression of astrocyte-specific protein (GFAP)
was demonstrated in glial cells [9]. In addition, the pres-
ence of microglia in the fetal rat brain was demonstrated
at the embryonic day 17 or 18 [10].
Several studies have shown a link between intrauterine
infection and cerebral white matter lesions or cerebral
palsy in preterm neonates [11-13]. Inflammatory
responses may directly affect the immature brain, in addi-
tion to neuronal damage after cerebral ischemia. It was
shown that the incidence of immature babies, suffering
from periventricular leukomalacia (PVL), was signifi-
cantly increased after chorioamnionitis [14-16]. In endo-
toxin-mediated leukoencephalopathy in full-term kittens,
the cerebral damage occurred during the postnatal period
(2–20 day-old of life) [17] and in neonatal dogs, of 1–10
days old, with marked inflammatory infiltrates [18]. More
recently, it was reported that ascending intrauterine infec-
tion with E. Coli caused fetal white matter damage in rab-
bits; these lesions were observed in 6% of live fetus
[19,20].
Astrocytes and microglia, which are the major glial cells in
the CNS, are involved in the regulation of the viability,
function and differentiation of progenitor cells under
physiological conditions. However, they also mediate
cytotoxic effect on oligodendrocytes under pathological
conditions, by production of pro-inflammatory cytokines
[4]. Glia cells are responsible for the deposition of myelin
in the CNS during development [21]. Damage of these
cells could result in an inadequate amount of myelin and/
or abnormal myelin. Therefore, patients suffering from
PVL develop cerebral palsy and impaired cognition during
development [22]. It was demonstrated that progenitor
oligodendrocytes are more sensitive to cytokine-induced
apoptosis than mature oligodendrocytes [23]. Therefore,
pathological conditions, such as maternal infection/
inflammation may damage progenitor cells or disturb
their maturation, and thus affect brain development [2,4].
Mechanisms of brain damage
Intrauterine infection was suggested to affect the imma-
ture brains by leading to cerebral hypoperfusion, which
may results in a hypoxic-ischemic brain damage, and/or
by inducing the production of pro-inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-α),
interleukin (IL)-1 and IL-6 from astrocytes and microglia.
These cytokines could damage oligodendrocyte progeni-
tors and thus induce PVL [2]. Also, upregulation of archi-
donic acid metabolism in brain tissue, or activated
leukocytes after ischemia may induce the production of
oxygen radicals [24]. The effect of these molecules in neu-
ronal cell damage, neurogenesis and neurodifferentiation,
in the developing brain has been demonstrated [25,26].
PVL is a predominant form of brain white matter lesion in
preterm infants [4]. It is characterized by small and multi-
focal regions of necrosis [27]. Astroglia and myelin are
important components of the white matter. Inflammation
of the CNS is characterized by reactive astrogliosis, typi-
fied by astrocyte proliferation or astrocytic hypertrophy
[28]. These features are under regulation of pro-inflam-
matory cytokines [29]. In addition, it was shown that
occurrence of PVL is associated with increased number of
astrocytes in the white matter lesion of infant brains [30].
The origin of the high levels of the pro-inflammatory
cytokines in the fetal brain could be the maternal uterus
and placenta, following intrauterine infection/inflamma-
tion, and/or the stimulated fetal brain microglia and
astrocytes [15,31]. It should be emphasized that not all
the elevated cytokines in the maternal uterus and placenta
are also elevated in the fetal brain.
Systemic maternal administration of lipopolysaccharide
(LPS) affected the myelination and astrogliosis in the neo-
natal rat brain [32]. In addition, IL-1, at physiological
doses, inhibited normal rat oligodendrocytes [33,34]. IL-
1 stimulates astrocytes growth and increases the appear-
ance of GFAP-reactive astrocytes [34,35]. These observa-
tions may suggest a potential role of cytokines in
mediating maternal infection and PVL injury in newborn
infants.
The expression of IL-1β and TNF-α mRNA was elevated, in
the fetal brain, following maternal LPS administration. InReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/17
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Possible mechanisms involved in the effect of intrauterine infection during pregnancy and offspring brain damage and  development Figure 1
Possible mechanisms involved in the effect of intrauterine infection during pregnancy and offspring brain damage and 
development.
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addition, the glial fibrillary acidic protein-positive astro-
cytes levels were increased and the myelin basic protein
levels were decreased in the brains of offspring [32]. It was
suggested that maternal or placental infection might
induce neonatal brain damage by increasing the pro-
inflammatory cytokines levels [15]. Recently, higher levels
of TNF-α, IL-1 and IL-6 were detected in brains with PVL
than in healthy [36]. In addition, it was observed that
newborns with brains white matter lesions belonged to
mothers with high levels of pro-inflammatory cytokines
in the amniotic fluid (AF), however newborns without
white matter lesions belonged to mother with normal lev-
els of the examined cytokines [37]. In addition, induced
intrauterine infection of rabbits, with bacteria, leads to
fetal brain white matter lesions [20].
TNF-α has been shown to increase permeability [38] and
to cross the blood-brain barrier [39]. It also reduces cere-
bral oxygen uptake, increases intracranial pressure [40],
induces diffuse intravascular coagulopathy, and increases
capillary permeability resulting in cerebral edema [41].
TNF-α is considered a potent cytotoxic agent in neuronal
tissue [42]. Expression of TNF-α was demonstrated in
brains of developing fetuses after an inflammatory stimu-
lation, and in autopsy specimens of children with PVL
[43]. TNF-α was shown to decrease the number of oli-
godendrocyte progenitors, also causing apoptosis of oli-
godendrocytes [43-45]. Incubation of hippocampal slices,
from mature fetal guinea pig, with LPS increased their
capacity to secrete TNF-α. It was suggested that the
released TNF-α in these slices might induce apoptotic
processes in oligodendrocytes and their progenitors
[31,46]. In addition, the combined application of TNF-α
and interferon-γ severely reduced survival and inhibited
differentiation of oligodendrocyte progenitors in primary
culture prepared from neonatal rats, thus may underlie
the disrupted myelination that characterizes PVL [12].
Also, higher levels of B-lymphocyte chemoattractant, cili-
ary neurotrophic factor (CNTF), epidermal growth fac-
tors, IL-12, IL-15, monocyte chemoattractant protein-3
and others were demonstrated in sera of children with CP
[47].
Involvement of angiogenic and neurotrophic 
factors in brain development
Neurotrophic factors are a family of proteins, which are
involved in the regulation of cell survival and pro-
grammed neuronal cell death during development [48].
The capacity of various neurotrophic factors to affect neu-
rons is often developmentally regulated [49]. Some of
these factors including brain derived neurotrophic factor
(BDNF) and nerve growth factor (NGF) [50,51] were
demonstrated as neuroprotective in experimental models
of hypoxia-ischemia. The levels of BDNF were decreased
in CA1 neurons of the hippocampus, following hypoxia-
ischemia; this was followed by onset of DNA fragmenta-
tion and subsequent neuronal death. On the other hand,
most of the BDNF-immunopositive neurons did not
undergo apoptosis after hypoxia-ischemia [52]. Astrocytes
are known to release neurotrophic factors such as platelet-
derived growth factor (PDGF), CNTF, BDNF, neuro-
trophins (NT)-3 and NT-4 [53,54], all of which have been
reported to support proliferation and survival of oli-
godendrocyte progenitor cells [55,56]. LPS was shown to
disturb the development of these cells, or even to be cyto-
toxic, by inducing astrocytes or microglia to produce pro-
inflammatory factors such as TNF-α, IL-1β, IL-6 and nitric
oxide (NO). In addition, LPS could induce cytotoxicity by
suppressing the production of neurotrophic factors by
astrocytes [4].
The process of angiogenesis drives maturation and elabo-
ration of the primary vascular network via proliferation
and migration of endothelial cells [57]. Vascular endothe-
lial growth factor (VEGF), is a polypeptide growth factor,
which acts as an endothelial cell survival factor and a vas-
cular permeability factor [58]. In addition, VEGF regulate
angiogenesis when acting in combination with other fac-
tors such as angiopoietin (Ang)-1 and -2 [59]. Although
several growth factors and cytokines influence the expres-
sion of VEGF, tissue hypoxia is suggested as the major
stimulating factor for the upregulation of VEGF in vivo
[60].
Endothelin-1 (ET-1) is one of the most potent vasocon-
strictors known [61]. ET-1 is a mitogenic [62] and anti-
apoptotic factor [63] in many cell types including
endothelial cells and astrocytes. Within the CNS, ET-1 was
demonstrated in various neuronal groups [64,65] and in
glial cells under pathological conditions [66]. Under
ischemia and Alzheimer's disease, ET-like immunoreactiv-
ity has been detected in astrocytes [67,68]. ET-1 was sug-
gested to play a key role in the development of cerebral
vasospasm [69]. Proinflammatory cytokines such as IL-1,
TNF-α and transforming growth factor-β, which are pro-
duced during endotoxemia, are also increased the produc-
tion of ET-1 from endothelial cells [12]. Thus, it is
possible to suggest that ET could be one of the autocrine/
paracrine factors in the different brain regions of the fetus
that should be considered under intrauterine infection.
Nitric oxide (NO) plays an important role in the patho-
genesis of neuronal injury during cerebral ischemia. NO is
the product of enzymatic activity of the constitutive
endothelial NO synthase (eNOS), neuronal (nNOS) and
inducible (iNOS) isoforms of this enzyme. After ischemia,
NO was associated with cerebral vasodilatation (via
inducing eNOS activity), and inhibition of platelet aggre-
gation and leukocyte adhesion (via activation of nNOS in
neurons and iNOS in microglia and astrocytes) [70,71].Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/17
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During development, the expression of nNOS parallels
that of the glutamate receptor and corresponds to regions
of selective vulnerability to hypoxia-ischemia [70,71].
Destruction of neurons containing nNOS in the neonatal
rat prior to hypoxia-ischemia lowered the injury score and
the frank infraction in the cortex [70,71]. In addition,
neonatal mice with targeted destruction of the nNOS gene
were markedly protected from injury to neurons in hip-
pocampus and cortex, when also subjected to hypoxia-
ischemia insult. The influx of intracellular calcium is
increased during cerebral ischemia, and results in activa-
tion of nitric oxide-synthase (NOS) and the production
NO. NO, like free iron, can increase the toxicity of super-
oxide radicals, and thus cause neuronal cell damage [70-
72].
Apoptosis in the developed brain (under normal physio-
logical conditions) is believed to occur mostly during pre-
natal development, decline early post-natally and to be
minimal in adult brain [71,72]. Ischemia and many other
acute and chronic neurodegenerative processes trigger
apoptosis [70,71]. Regulation of caspase-3 by BDNF was
demonstrated in the neuronal cell bodies and in the stria-
tum and hippocampus following hypoxia-ischemia [83].
Also, upregulation of CD95 (FasL) (the cell surface recep-
tor which induces apoptotic death) was demonstrated in
the hippocampus, and thalamus following hypoxia-
ischemia injury to the developing rat brain [70,71,74].
The neuropeptides alpha-melanocyte-stimulating hor-
mone (α-MSH) is a proopiomelanocortin derivate that
show anti-inflammatory effect within the brain. It regu-
lates and mediates the communication between nervous,
endocrine and immune system. It is produced by pituitary
cells, neurons, keratinocytes and macrophages [75]. The
anti-inflammatory activity of a-MSH was demonstrated in
different disease including endotoxemia/ischemia [75-
77]. The anti-inflammatory activity of α-MSH include
suppression of inflammatory cytokine expression such as
TNF-α, interferon-γ, IL-1, IL-6 and IL-8, and also the inhi-
bition of inflammatory activity of neutrophils and mono-
cytes [75,77]. It also blocked LPS-induced expression of
TNF-a [78]. In addition, α-MSH was upregulated the anti-
inflammatory cytokine IL-10 [79]. Recently, it was dem-
onstrated that α-MSH levels were decreased in plasma of
patients with acute brain injury; these levels were in a neg-
ative correlation with TNF-α levels [80]. It was also shown
that α-MSH acts directly within the brain (through micro-
glia) to modulate local inflammation [81]. Alpha-MSH
was demonstrated to inhibit brain tumor necrosis factor-
alpha (TNF-alpha), which is involved in human neurode-
generative diseases, induced by local injection of lipopol-
ysaccharide. Ischemia/reperfusion of the brain was shown
to induce inflammation in the CNS, and application of α-
MSH (systemically) modulated this process. It was dem-
onstrated that such influences of the peptide may occur
through inhibition of inflammatory agents produced by
glia. Alpha-MSH modulated TNF-alpha and nitric oxide
produced by activated murine microglia, and TNF-alpha
produced by human astrocytes. Since glial cells can secrete
an d react to alpha-MSH, it is suggested that these cells act
as autocrine regulatory element, which can regulate both
fever and inflammation in the brain [82-84].
Thus, it is possible to suggest that α-MSH could be
involved in the regulation of the inflammatory processes
in the fetal brains of mothers with intrauterine infection,
and to be suggested as a possible treatment of CNS disor-
ders that have an inflammatory component.
The involvement of the above factors and mechanisms in
the pathophysiology of intrauterine infection during preg-
nancy and offspring brain damage and development is
not yet clear.
Maternal infection/inflammation and offspring 
development
The association between systemic perinatal infection and
cognitive limitations among preterm infants is not yet
clear. It has been shown that intrauterine infection and
the fetal inflammatory response are associated with an
increased risk of preterm birth, which is in turn is associ-
ated with poor cognitive and perceptual outcome of the
preterm newborn [85]. Therefore, it is suggested that
intrauterine infection can impair brain development in a
manner that may also affect cognitive ability. Cerebral
white matter is most closely associated with long-term
neuromotor, cognitive, and behavioral limitations in pre-
term infants [97]. Nevertheless, some infants exposed to
perinatal infection, which do not develop white matter
damage, might suffer immaturity-related neuronal dam-
age, neuronal disorganization, and excessive neuronal-
programmed cell death, abnormal synaptogenesis, den-
dritic simplification, and abnormalities in neurotransmit-
ters [85].
In addition, it was shown that exposure of animals to
products of infection/inflammation induced cognitive
deficits. In Wistar rats, the exposure to pyrogens, includ-
ing LPS and IL-1β, interrupted task acquisition when
administered during the learning process, but not thereaf-
ter [85,86]. Since the biomolecular signals regulated by
inflammatory cytokines and leading to behavioral abnor-
malities are not yet clear, it is suggested that interruption
of the proinflammatory cytokine cascade might prevent
brain damage and impaired development.
Therapeutic possibilities
The relationship between brain damages of offspring fol-
lowing maternal infection/inflammation duringReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/17
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pregnancy is not yet clear. Therefore, some of the sug-
gested therapeutic possibilities are based on possible
mechanisms of the offspring brain damages.
Since maternal infection/inflammation increases off-
spring brain cytokines, which may lead to a cascade of
events (as described previously), that could injure the off-
spring's brains, it is possible to suggest anti-inflammatory
cytokines and/or specific inhibitors of intracellular event
such as free radical synthesis or scavengers, NOS inhibi-
tors and/or scavengers and anti apoptotic agents as possi-
ble prevention/therapeutic agents.
Possible therapeutic interventions may also include sup-
plementation of trophic factors, which may increase sur-
vival and differentiation of oligodendrocyte precursors, as
well as anti-inflammatory agents.
It should be emphasized that other mechanism such as
increased maternal temperature, placental endothelial
damage and increased coagulation tendency, fetal
hypoxia or acidosis, fetal hypotension and others may
also aggravate fetal brain damage. In addition, we did not
consider, in this review, the viral infections which also
could result in brain damage.
In summary, it is possible to hypotheses that intrauterine
infection/inflammation during pregnancy may lead to
newborn, adult and aged offspring brain damages (Fig. 1).
This may affect morphogenic and behavioral phenotypes
of the developed offspring. The offspring brain damage
could be mediated through up-regulation of pro-inflam-
matory cytokine production in the circulation and in the
brain of the fetal/offspring. These pro-inflammatory
cytokines could, by one hand, decrease the production of
neurotrophic factors such as NGF and BDNF and, by other
hand, to increase the production of NO, VEGF and PGE.
These factors increase apoptosis and also may lead to vas-
cularization/angiogenesis defects. Affecting these func-
tions in the brain may lead to compartment/site brain
damage, which may, during a developmental window,
lead to some neurological diseases and/or cognitive
defects.
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